Anula Jayasuriya - 01 Jul 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director
Signature
/s/ Alexandra Hernandez, as Attorney-in Fact
Issuer symbol
LCTX
Transactions as of
01 Jul 2023
Transactions value $
$0
Form type
4
Filing time
03 Jul 2023, 17:45:57 UTC
Previous filing
06 Apr 2023
Next filing
02 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 01 Jul 2023 Common Shares 50,000 $1.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer.